Ordaõs Looks To Unlock The Therapeutic Promise Of Mini-Proteins

 
• By Joseph Haas

Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.

Camelid antibody
Mini-proteins are based on naturally occuring single-chain antibodies in camelids • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs